Drug
Eribulin
Eribulin: highest development phase Phase 2, developed by Eisai, United Therapeutics. 3 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Eisai, United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Eribulin NCT03637868 | Phase 2 | Metastatic Breast Cancer |
| Eribulin mesylate NCT01323530 | Phase 1/2 | Metastatic Breast Cancer |
| Eribulin Mesylate NCT02513472 | Phase 1/2 | Breast Neoplasm |
Latest
No recent events.
Follow Eribulin on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.